These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 15691540)

  • 1. A mathematical model of Doxorubicin treatment efficacy for non-Hodgkin's lymphoma: investigation of the current protocol through theoretical modelling results.
    Ribba B; Marron K; Agur Z; Alarcón T; Maini PK
    Bull Math Biol; 2005 Jan; 67(1):79-99. PubMed ID: 15691540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Primary non-Hodgkin's lymphoma of the nasal cavity at early stage: long-term treatment outcomes and prognostic analyses of 108 cases].
    He YF; Zhang YJ; Li YH; Lin TY; Xia YF; Lu TX; Huang HQ; Jiang WQ; Xian CG; He YJ; Guan ZZ
    Ai Zheng; 2006 Dec; 25(12):1538-42. PubMed ID: 17166382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma].
    Zhou SY; Shi YK; He XH; Zhang P; Dong M; Huang DZ; Yang JL; Zhang CG; Liu P; Yang S; Feng FY
    Ai Zheng; 2005 Apr; 24(4):465-9. PubMed ID: 15820071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term outcome of localized high-grade non-Hodgkin's lymphoma treated with high dose CHOP regimen and involved field radiotherapy: results of a GOELAMS study.
    Bernard M; Cartron G; Rachieru P; LeMevel A; Branger B; Le Maignan C; Berthou C; Ghandour C; Delwail V; Milpied N; Cassasus P; Celigny PS; Guyotat D; Lamy T; Desablens B;
    Haematologica; 2005 Jun; 90(6):802-9. PubMed ID: 15951293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel methionine aminopeptidase-2 inhibitor, PPI-2458, inhibits non-Hodgkin's lymphoma cell proliferation in vitro and in vivo.
    Cooper AC; Karp RM; Clark EJ; Taghizadeh NR; Hoyt JG; Labenski MT; Murray MJ; Hannig G; Westlin WF; Thompson CD
    Clin Cancer Res; 2006 Apr; 12(8):2583-90. PubMed ID: 16638869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab plus ASHAP for the treatment of patients with relapsed or refractory aggressive non-Hodgkin's lymphoma: a single-centre study of 20 patients.
    Aydin S; Dührsen U; Nückel H
    Ann Hematol; 2007 Apr; 86(4):271-6. PubMed ID: 17216473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of involved field radiotherapy in partial response after doxorubicin-based chemotherapy for advanced aggressive non-Hodgkin's lymphoma.
    Moser EC; Kluin-Nelemans HC; Carde P; Meerwaldt JH; Tirelli U; Aleman BM; Baars J; Thomas J; van Glabbeke M; Noordijk EM
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1168-77. PubMed ID: 16887289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
    Marcus R; Hagenbeek A
    Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective, non-randomised phase 1-2 trial of VACOP-B with filgrastim support for HIV-related non-Hodgkin's lymphoma.
    Sawka CA; Shepherd FA; Franssen E; Brandwein J; Dotten DA; Routy JP; Walker IR; St-Louis J; Taylor M; Arts K; Crump M; Foote M
    Biotechnol Annu Rev; 2005; 11():381-9. PubMed ID: 16216784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].
    Zou GR; Zhang YJ; Xie FY; Zheng W; Li HX; Xia YF; Lin TY; Lu TX
    Ai Zheng; 2006 Dec; 25(12):1543-9. PubMed ID: 17166383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increasing chemotherapy dose density and intensity: phase I trials in non-small cell lung cancer and non-Hodgkin's lymphoma.
    Blayney DW; McGuire BW; Cruickshank SE; Johnson DH
    Oncologist; 2005 Feb; 10(2):138-49. PubMed ID: 15709216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Long-term outcomes of 392 non-Hodgkin's lymphoma patients treated with pirarubicin based regimens].
    Huang HQ; Peng YL; Cai QQ; Lin XB; Li YH; Xia ZJ; Lin TY; Sun XF; Zhang L; Xu GC; He YJ; Jiang WQ; Guan ZZ
    Zhonghua Xue Ye Xue Za Zhi; 2005 Oct; 26(10):577-80. PubMed ID: 16532963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical outcomes of different regimens for non-Hodgkin's lymphoma with bone marrow involvement: analysis of 148 cases].
    Li QC; Yuan XL; Wang YF; Zou DH; Zhao YZ; Qiu LG
    Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(4):254-7. PubMed ID: 18361837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time-dependent effect of non-Hodgkin's lymphoma grade on disease-free survival of relapsed/refractory patients treated with high-dose chemotherapy plus autotransplantation.
    Fu P; van Heeckeren WJ; Wadhwa PD; Bajor DJ; Creger RJ; Xu Z; Cooper BW; Laughlin MJ; Gerson SL; Koç ON; Lazarus HM
    Contemp Clin Trials; 2008 Mar; 29(2):157-64. PubMed ID: 17707140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prognostic factors of invasive non-Hodgkin's lymphoma].
    Yu H; Hong XN; Li J; Peng LP; Ye L
    Zhonghua Zhong Liu Za Zhi; 2007 Jun; 29(6):461-3. PubMed ID: 17974284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Non-Hodgkin's lymphomas of the digestive tract and anexal glands in AIDS patients].
    Corti M; Villafañe Fioti MF; Lewi D; Schtirbu R; Narbaitz M; de Dios Soler M
    Acta Gastroenterol Latinoam; 2006 Dec; 36(4):190-6. PubMed ID: 17225446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
    Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
    Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Receptors for luteinizing hormone releasing hormone (LHRH) expressed in human non-Hodgkin's lymphomas can be targeted for therapy with the cytotoxic LHRH analogue AN-207.
    Keller G; Schally AV; Gaiser T; Nagy A; Baker B; Halmos G; Engel JB
    Eur J Cancer; 2005 Sep; 41(14):2196-202. PubMed ID: 16182122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnosis and grading of non-Hodgkin's lymphomas on fine needle aspiration cytology.
    Mathur S; Dawar R; Verma K
    Indian J Pathol Microbiol; 2007 Jan; 50(1):46-50. PubMed ID: 17474258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.